World Pharma News Digest - 28.09.2009

0 views
Skip to first unread message

Ruslan David

unread,
Sep 28, 2009, 5:57:45 AM9/28/09
to worldph...@googlegroups.com
Abbott to Acquire Solvay Pharmaceuticals Business 
Abbott today announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion ($6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets. 
Read more... 
http://www.worldpharmanews.com/content/view/953/1/
 
Novartis bronchodilator QAB149 recommended for approval in European Union 
Novartis has received a positive opinion recommending European Union (EU) approval of QAB149 (indacaterol) for maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). When approved, QAB149 and its device, Concept-1, will be known as Onbrez® Breezhaler®[§]. 
Read more... 
http://www.worldpharmanews.com/content/view/952/1/
 
Results from Abbott's PROSPECT Study Provide New Insight 
Abbott (NYSE: ABT) announced primary results from its ground breaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease. 
Read more... 
http://www.worldpharmanews.com/content/view/951/1/
 
Herceptin provides impressive survival benefit for patients with high levels of HER2 
A detailed analysis of the Phase III ToGA study revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). 
Read more... 
http://www.worldpharmanews.com/content/view/950/1/
 
Results of ADAGIO study with Azilect® in Parkinson's disease published 
H. Lundbeck A/S' (Lundbeck) partner Teva Phamaceuticals Industries Ltd. (Teva) announced that results from the ADAGIO trial, published online in The New England Journal of Medicine, demonstrated that Parkinson's disease patients receiving Azilect® (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed-start group)(1). 
Read more... 
http://www.worldpharmanews.com/content/view/949/1/
 
Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival 
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo controlled Phase II trial showing that Nexavar® (sorafenib tablets) in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer by 74 percent. 
Read more... 
http://www.worldpharmanews.com/content/view/948/1/
 
Analysis of BRAIN study shows that patients may have a stabilisation or improvement 
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that an analysis of the phase II BRAIN study of Avastin (bevacizumab) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM) demonstrated that in addition to increasing the chance of patients being alive without worsening of their disease at six months (progression free survival; PFS-6*(1), Avastin-based therapy may also lead to additional positive impact on patients' daily lives(2). 
Read more... 
http://www.worldpharmanews.com/content/view/947/1/
 
Denosumab Demonstrates Superiority Over Zometa(R) 
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. 
Read more... 
http://www.worldpharmanews.com/content/view/946/1/
 
Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim 
Pfizer Inc (NYSE: PFE) and Wyeth (NYSE: WYE) announced that they have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer's pending acquisition of Wyeth. 
Read more... 
http://www.worldpharmanews.com/content/view/945/1/
 
PharmaNews.eu / Latest News
 
 
 
European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1) 2009
http://www.pharmanews.eu/emea/332-european-medicines-agency-recommends-authorisation-of-two-vaccines-for-influenza-pandemic-h1n1-2009
 
 
Nexavar® Demonstrates 74 Percent Improvement in Progression-Free Survival
http://www.pharmanews.eu/bayer/330-nexavarr-demonstrates-74-percent-improvement-in-progression-free-survival
 
Boehringer Ingelheim Animal Health enters into agreement to acquire certain assets of Fort Dodge Animal Health from Pfizer
http://www.pharmanews.eu/boehringer-ingelheim/329-boehringer-ingelheim-animal-health-enters-into-agreement-to-acquire-certain-assets-of-fort-dodge-animal-health-from-pfizer
 
Nycomed sustains commitment to Russia-CIS and invests in new pharmaceutical production plant
http://www.pharmanews.eu/nycomed/328-nycomed-sustains-commitment-to-russia-cis-and-invests-in-new-pharmaceutical-production-plant
 
Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim
http://www.pharmanews.eu/pfizer/327-pfizer-and-wyeth-to-divest-certain-animal-health-assets-to-boehringer-ingelheim
 
 
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
 
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages